Ocugen (OCGN) Income from Continuing Operations (2014 - 2026)
Ocugen (OCGN) posted Income from Continuing Operations of 35859000.0 for Q1 2026, down 98.84% on a QoQ basis from 18034000.0 in Q4 2025, and down 131.98% year-over-year from 112140081.33 in Q1 2025.
Ocugen (OCGN) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Ocugen's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 35859000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 131.98% year-over-year to 35859000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92767000.0 (down 46.4% YoY) and the FY2025 annual result came in at 198039000.0, down 14.43% from the prior year.
- Income from Continuing Operations was 35859000.0 for Q1 2026 at Ocugen, down from 18034000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12981000.0 in Q3 2024 and bottomed at 123938000.0 in Q4 2023.
- A 5-year average of 27698411.76 and a median of 20985000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 464.92% — and 2024, when it jumped 88.75%.
- Ocugen's Income from Continuing Operations stood at 21939000.0 in 2022, then sank by 464.92% to 123938000.0 in 2023, then soared by 88.75% to 13941000.0 in 2024, then retreated by 29.36% to 18034000.0 in 2025, then plunged by 98.84% to 35859000.0 in 2026.
- Business Quant data shows OCGN's Income from Continuing Operations at 35859000.0 in Q1 2026, 18034000.0 in Q4 2025, and 18732000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Ocugen | 63.79 Mn | 63.79 Mn | - | -35.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.86 Mn |
| Dec 31, 2025 | -18.03 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -20.14 Mn |
| Mar 31, 2025 | -15.46 Mn |
| Dec 31, 2024 | -13.94 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Jun 30, 2024 | -20.99 Mn |
| Mar 31, 2024 | -18.41 Mn |
| Dec 31, 2023 | -123.94 Mn |
| Sep 30, 2023 | -16.87 Mn |
| Jun 30, 2023 | -28.17 Mn |
| Mar 31, 2023 | -22.85 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -27.15 Mn |
| Mar 31, 2022 | -33.50 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |
| Jun 30, 2021 | -85.16 Mn |